Log in

Relevant bibliographies by topics / Entacapona / Journal articles

To see the other types of publications on this topic, follow the link: Entacapona.

Journal articles on the topic 'Entacapona'

Author: Grafiati

Published: 4 June 2021

Last updated: 13 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Entacapona.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Tkach, Volodymyr V., Sílvio C. De Oliveira, Marta V. Kushnir, et al. "A descrição matemática do desempenho eletroanalítico do compósito poli(alaranjado da acridina)-oxihidróxido de vanádio na detecção eletrorredutiva da entacapona." Revista Colombiana de Ciencias Químico-Farmacéuticas 48, no. 2 (2019): 455–66. http://dx.doi.org/10.15446/rcciquifa.v48n2.82724.

Full text

Abstract:

Por meio de uma análise teórica, foi avaliado o desempenho do compósito do oxihidróxido do vanádio trivalente com o polímero do corante alaranjado da acridina, na detecção eletroquímica do fármaco antiparquinsônico entacapona. O processo eletroanalítico é baseado na eletrorredução do fármaco mencionado. Do desenvolvimento e da análise do modelo matemático correspondente, mediante a teoria de estabilidade linear e anáise de bifurcações, foi possível concluir que o compósito pode ser um modificador eficiente para a determinação da entacapona. Os comportamentos oscilatórios e monotônico, neste si

APA, Harvard, Vancouver, ISO, and other styles

2

Kulisevsky Bojarsky, Jaume, Juan Andrés Burguera Hernández, Mª Rosario Luquin Piudo, et al. "Entacapona: ¿es útil como tratamiento complementario a la levodopa?" Revista de Neurología 28, no. 08 (1999): 817. http://dx.doi.org/10.33588/rn.2808.99183.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Martínez-Martín, P., B. Hernández, and J. Ricart. "Factores determinantes del inicio de tratamiento con levodopa/carbidopa/entacapona en pacientes españoles con enfermedad de Parkinson." Neurología 29, no. 3 (2014): 153–60. http://dx.doi.org/10.1016/j.nrl.2012.12.008.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Custodio, Nilton, Rosa Montesinos, David Lira, and Hernando Torres. "Hipersexualidad asociada a pramipexol, en el tratamiento de síntomas parkinsonianos: revisión de la literatura, a propósito de 3 casos." Anales de la Facultad de Medicina 71, no. 1 (2011): 51. http://dx.doi.org/10.15381/anales.v71i1.72.

Full text

Abstract:

Introducción: Los desórdenes del control de los impulsos han sido reportados en pacientes con enfermedad de Parkinson (EP), así como en usuarios de agonistas dopaminérgicos. Comunicamos tres casos de pacientes con síntomas parkinsonianos e hipersexualidad, un desorden del control de los impulsos, asociado al uso de pramipexol. Casos clínicos: Caso 1: Varón de 62 años de edad con EP en tratamiento con levodopa/carbidopa, que requirió inicio de pramipexol; a los doce meses presentó hipersexualidad que remitió parcialmente con escitalopram. Caso 2: Varón de 66 años de edad con EP en tratamiento c

APA, Harvard, Vancouver, ISO, and other styles

5

Horga de la Parte, José Francisco. "Entacapona: un nuevo inhibidor de catecol-O-metiltransferasa que mejora la respuesta a levodopa en pacientes parkinsonianos con fluctuaciones motoras." Revista de Neurología 28, no. 05 (1999): 499. http://dx.doi.org/10.33588/rn.2805.99104.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Claverie, S., and A. Giacchino. "Iniciar terapia con levodopa/carbidopa con y sin entacapona a principios de la enfermedad de Parkinson. El estudio STRIDE-PD." Neurología Argentina 2, no. 3 (2010): 214. http://dx.doi.org/10.1016/s1853-0028(10)70065-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Chávez-León, Enrique, Martha Patricia Ontiveros-Uribe, and José Damián Carrillo-Ruiz. "La enfermedad de Parkinson: neurología para psiquiatras." Salud Mental 36, no. 4 (2013): 315. http://dx.doi.org/10.17711/sm.0185-3325.2013.038.

Full text

Abstract:

La enfermedad de Parkinson es una enfermedad degenerativa y progresiva debida a la pérdida de las neuronas dopaminérgicas de la sustancia nigra del mesencéfalo. Sus manifestaciones son: temblor en reposo, rigidez y enlentecimiento de los movimientos, alteraciones en la postura y en la marcha. La aparición temprana de problemas en la memoria o alucinaciones, no debidas al tratamiento, indica la presencia de demencia con cuerpos de Lewy. Las escalas utilizadas para evaluar el estadio y la gravedad de la enfermedad de Parkinson son: la Escala de los Estadios de Hoehn y Yahr y la Escala Unificada

APA, Harvard, Vancouver, ISO, and other styles

8

Paim, Clés S., Eduardo C. Palma, Marcelo D. Malesuik, and Martin Steppe. "LC/MS/MS Study for Identification of Entacapone Degradation Product Obtained by Photodegradation Kinetics." Journal of AOAC INTERNATIONAL 93, no. 6 (2010): 1856–61. http://dx.doi.org/10.1093/jaoac/93.6.1856.

Full text

Abstract:

Abstract Entacapone is indicated for clinical use as an adjunct to levodopa/carbidopa to treat patients with idiopathic Parkinson's Disease who experience the signs and symptoms of end-of-dose wearing-off. The aim of this study was to determine the photodegradation kinetics and to elucidate the structure of the main degradation product. The stability of entacapone was studied in order to investigate the degradation kinetics of this drug using LC as a stability indicator. Entacapone was subjected to accelerated photodegradation. This study was carried out with methanolic solutions, prepared fro

APA, Harvard, Vancouver, ISO, and other styles

9

Yoo, Dae Young, Hyo Young Jung, Woosuk Kim, et al. "Entacapone Treatment Modulates Hippocampal Proteins Related to Synaptic Vehicle Trafficking." Cells 9, no. 12 (2020): 2712. http://dx.doi.org/10.3390/cells9122712.

Full text

Abstract:

Entacapone, a reversible inhibitor of catechol-O-methyl transferase, is used for patients in Parkinson’s disease because it increases the bioavailability and effectiveness of levodopa. In the present study, we observed that entacapone increases novel object recognition and neuroblasts in the hippocampus. In the present study, two-dimensional electrophoresis (2-DE) and matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry were performed to compare the abundance profiles of proteins expressed in the hippocampus after entacapone treatment in mice. Results of 2-D

APA, Harvard, Vancouver, ISO, and other styles

10

Sieb, J. P., and T. Müller. "Die fixe Kombination von Levodopa/Carbidopa mit Entacapon in der Parkinson-Therapie." Nervenheilkunde 23, no. 03 (2004): 174–80. http://dx.doi.org/10.1055/s-0038-1626290.

Full text

Abstract:

ZusammenfassungDer Catechol-O-Methyltransferase-Hemmer Entacapon ist eine in der medikamentösen Parkinsontherapie etablierte Substanz. Sie erweitert das therapeutische Spektrum durch Hemmung des Abbaus von Levodopa (LD) in der Peripherie, womit die Wirkung von LD verstärkt wird. Entacapon ist nur in Kombination mit LD und besonders bei Patienten mit vorhersagbaren Fluktuationen der Beweglichkeit wirksam. Nebenwirkungen können eine Verstärkung von Dyskinesien, Diarrhoe, Blutdruckabfall und Urinverfärbung sein. Da Entacapon meist gleichzeitig mit jeder LD/Decarboxylasehemmer (DCH)-Dosis verabrei

APA, Harvard, Vancouver, ISO, and other styles

11

Peng, Shiming, Wen Xiao, Dapeng Ju, et al. "Identification of entacapone as a chemical inhibitor of FTO mediating metabolic regulation through FOXO1." Science Translational Medicine 11, no. 488 (2019): eaau7116. http://dx.doi.org/10.1126/scitranslmed.aau7116.

Full text

Abstract:

Recent studies have established the involvement of the fat mass and obesity-associated gene (FTO) in metabolic disorders such as obesity and diabetes. However, the precise molecular mechanism by which FTO regulates metabolism remains unknown. Here, we used a structure-based virtual screening of U.S. Food and Drug Administration–approved drugs to identify entacapone as a potential FTO inhibitor. Using structural and biochemical studies, we showed that entacapone directly bound to FTO and inhibited FTO activity in vitro. Furthermore, entacapone administration reduced body weight and lowered fast

APA, Harvard, Vancouver, ISO, and other styles

12

Schnitker, Jörg, and Thomas Müller. "Meta-analysis of Placebo-controlled Clinical Trials of Safinamide and Entacapone as Add-on Therapy to Levodopa in the Treatment of Parkinson’s Disease." European Neurological Review 10, no. 01 (2015): 15. http://dx.doi.org/10.17925/enr.2015.10.01.15.

Full text

Abstract:

Chronic levodopa (L-dopa) treatment of Parkinson’s disease (PD) patients is sooner or later associated with the onset of motor complications, for example wearing off and dyskinesia. PD patients with motor complications usually require the addition of further PD drugs to reduce these L-dopa side effects and enhance its efficacy. Entacapone is an available catechol-O-methyltransferase (COMT) inhibitor, which was extensively investigated as add-on to L-dopa/dopadecarboxylase inhibitor (DDCI) application in PD patients. Safinamide, a watersoluble, orally active a-aminoamide derivative, which modul

APA, Harvard, Vancouver, ISO, and other styles

13

Holm, Kristin J., and Caroline M. Spencer. "Entacapone." Drugs 58, no. 1 (1999): 159–77. http://dx.doi.org/10.2165/00003495-199958010-00017.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

&NA;. "Entacapone." Reactions Weekly &NA;, no. 942 (2003): 7. http://dx.doi.org/10.2165/00128415-200309420-00019.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

&NA;. "Entacapone." Reactions Weekly &NA;, no. 1234 (2009): 18–19. http://dx.doi.org/10.2165/00128415-200912340-00051.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

McNeely, Wendy, and Rick Davis. "Entacapone." CNS Drugs 8, no. 1 (1997): 79–88. http://dx.doi.org/10.2165/00023210-199708010-00006.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

&NA;. "Entacapone." CNS Drugs 8, no. 1 (1997): 89–90. http://dx.doi.org/10.2165/00023210-199708010-00008.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Chong, Barbara S., and Tracey L. Mersfelder. "Entacapone." Annals of Pharmacotherapy 34, no. 9 (2000): 1056–65. http://dx.doi.org/10.1345/aph.19328.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Müller, Thomas. "Entacapone." Expert Opinion on Drug Metabolism & Toxicology 6, no. 8 (2010): 983–93. http://dx.doi.org/10.1517/17425255.2010.502167.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Reichmann, H. "Entacapon." Aktuelle Neurologie 25, S 4 (1998): S273—S274. http://dx.doi.org/10.1055/s-2007-1017742.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Kammler, S., U. Achenbach, and G. Ulm. "Zur Langzeitwirksamkeit von Entacapon bei älteren Parkinson-Patienten." Nervenheilkunde 23, no. 04 (2004): 226–30. http://dx.doi.org/10.1055/s-0038-1626369.

Full text

Abstract:

ZusammenfassungIn Fortsetzung einer offenen Studie mit 40 älteren Parkinson-Patienten (> 70 Jahre), die u.a. wegen psychiatrischer Störungen oder Fluktuationen unter Dopaminagonisten auf Entacapon umgestellt worden waren, wurden 20 Patienten 1,5 Jahre nach Beginn der Entacapon-Therapie erneut untersucht. Das Erkrankungsstadium nach Hoehn & Yahr sank bei diesen Patienten von 4,0 zu Beginn auf 3,0 nach 3 Wochen und auf 2,5 nach 1,5 Jahren (Median). Der Schweregrad der Parkinson-Symptomatik, gemessen mittels WebsterSkala, sank von 19,5 zu Beginn auf 14,0 nach 3 Wochen und auf 11,5 nach 1,5

APA, Harvard, Vancouver, ISO, and other styles

22

&NA;. "Entacapone/tolcapone." Reactions Weekly &NA;, no. 1093 (2006): 14. http://dx.doi.org/10.2165/00128415-200610930-00047.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

&NA;. "Entacapone interaction." Reactions Weekly &NA;, no. 1182 (2007): 16. http://dx.doi.org/10.2165/00128415-200711820-00048.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Li, Bao-Dong, Jing-Jun Cui, Jia Song, et al. "Comparison of the Efficacy of Different Drugs on Non-Motor Symptoms of Parkinson’s Disease: a Network Meta-Analysis." Cellular Physiology and Biochemistry 45, no. 1 (2018): 119–30. http://dx.doi.org/10.1159/000486252.

Full text

Abstract:

Background/Aims: A network meta-analysis is used to compare the efficacy of ropinirole, rasagiline, rotigotine, entacapone, apomorphine, pramipexole, sumanirole, bromocriptine, piribedil and levodopa, with placebo as a control, for non-motor symptoms in Parkinson’s disease (PD). Methods: PubMed, Embase and the Cochrane Library were searched from their establishment dates up to January 2017 for randomized controlled trials (RCTs) investigating the efficacy of the above ten drugs on the non-motor symptoms of PD. A network meta-analysis combined the evidence from direct comparisons and indirect c

APA, Harvard, Vancouver, ISO, and other styles

25

&NA;. "Levodopa/carbidopa/entacapone." Reactions Weekly &NA;, no. 1233 (2009): 16–17. http://dx.doi.org/10.2165/00128415-200912330-00044.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

&NA;. "Levodopa/carbidopa/entacapone." Reactions Weekly &NA;, no. 1239 (2009): 20–21. http://dx.doi.org/10.2165/00128415-200912390-00061.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

&NA;. "Levodopa/carbidopa/entacapone." Reactions Weekly &NA;, no. 1414 (2012): 33. http://dx.doi.org/10.2165/00128415-201214140-00111.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Ferreira, Joaquim J., Andrew J. Lees, Werner Poewe, et al. "Effectiveness of opicapone and switching from entacapone in fluctuating Parkinson disease." Neurology 90, no. 21 (2018): e1849-e1857. http://dx.doi.org/10.1212/wnl.0000000000005557.

Full text

Abstract:

ObjectiveTo evaluate the effectiveness of opicapone as add-on to levodopa and the effects of switching from entacapone over 1 year of treatment in patients with fluctuating Parkinson disease.MethodsAfter completion of a placebo- and entacapone-controlled double-blind study of opicapone (5, 25, or 50 mg), 495 patients continued to a 1-year extension phase in which patients were treated with opicapone. Patients began with once-daily opicapone 25 mg for 1 week, followed by individually tailored levodopa and/or opicapone dose adjustments. The primary efficacy variable was the change from baseline

APA, Harvard, Vancouver, ISO, and other styles

29

Salama, Nahla N., Shereen M. Azab, Mona A. Mohamed, and Amany M. Fekry. "A novel methionine/palladium nanoparticle modified carbon paste electrode for simultaneous determination of three antiparkinson drugs." RSC Advances 5, no. 19 (2015): 14187–95. http://dx.doi.org/10.1039/c4ra15909h.

Full text

Abstract:

A simple and novel method for the simultaneous determination of entacapone (EN), levodopa (LD) and carbidopa (CD) based on a methionine/palladium nanoparticle modified carbon paste electrode is described.

APA, Harvard, Vancouver, ISO, and other styles

30

Trenkwalder, Claudia, Mikko Kuoppamäki, Mikko Vahteristo, Thomas Müller, and Juha Ellmén. "Increased dose of carbidopa with levodopa and entacapone improves “off” time in a randomized trial." Neurology 92, no. 13 (2019): e1487-e1496. http://dx.doi.org/10.1212/wnl.0000000000007173.

Full text

Abstract:

ObjectiveTo investigate whether increased fixed carbidopa doses of 65 or 105 mg (ODM-101/65 and ODM-101/105) in combination with 75, 100, 125, or 150 mg of levodopa and 200 mg of entacapone might improve “off” time in fluctuating Parkinson disease (PD) compared to the standard combination of 4:1 levodopa/carbidopa with the usual 200 mg of entacapone (LCE) during a 4-week treatment period.MethodsThis was a randomized, double-blind, double-dummy, active-controlled, crossover, multicenter, phase II, proof-of-concept study in patients with fluctuating PD.ResultsOne hundred seventeen patients were

APA, Harvard, Vancouver, ISO, and other styles

31

&NA;. "Levodopa/carbidopa/entacapone/rasagiline." Reactions Weekly &NA;, no. 1213 (2008): 23. http://dx.doi.org/10.2165/00128415-200812130-00066.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

&NA;. "Labelled warning for entacapone." Reactions Weekly &NA;, no. 731 (1998): 2. http://dx.doi.org/10.2165/00128415-199807310-00003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

&NA;. "Entacapone/levodopa/carbidopa withdrawal." Reactions Weekly &NA;, no. 1364 (2011): 19. http://dx.doi.org/10.2165/00128415-201113640-00071.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Hauser, R. A. "Levodopa/carbidopa/entacapone (Stalevo)." Neurology 62, Issue 1, Supplement 1 (2004): S64—S71. http://dx.doi.org/10.1212/wnl.62.1_suppl_1.s64.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Dalton, Jo. "Entacapone - levodopa's perfect partner?" Inpharma Weekly &NA;, no. 1264 (2000): 15–16. http://dx.doi.org/10.2165/00128413-200012640-00038.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Rivest, Jean, C. Lynn Barclay, and Oksana Suchowersky. "COMT Inhibitors in Parkinson's Disease." Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques 26, S2 (1999): S34—S38. http://dx.doi.org/10.1017/s031716710000007x.

Full text

Abstract:

The COMT inhibitors, tolcapone and entacapone, are a new class of Parkinson's medications. By inhibiting the enzyme catechol-o-methyl-transferase (COMT), they prevent peripheral degradation of levodopa, allowing a higher concentration to cross the blood-brain barrier. Pharmacokinetic studies have shown that both tolcapone and entacapone significantly prolong the elimination half life, and increase the area under the curve of levodopa without increasing C max. Clinical studies with COMT inhibitors have shown benefit in both stable and fluctuating PD patients with improvement in motor function w

APA, Harvard, Vancouver, ISO, and other styles

37

Sharif, Ashfaq A. "Entacapone in restless legs syndrome." Movement Disorders 17, no. 2 (2002): 421. http://dx.doi.org/10.1002/mds.10080.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Prous, J., X. Rabasseda, and J. Castañer. "Entacapone < Rec INN >." Drugs of the Future 19, no. 7 (1994): 641. http://dx.doi.org/10.1358/dof.1994.019.07.258368.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

&NA;. "Entacapone/Levodopa/Carbidopa Combination Tablet." Drugs in R & D 4, no. 5 (2003): 310–11. http://dx.doi.org/10.2165/00126839-200304050-00006.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Kwokal, Ana, and Kevin J. Roberts. "Direction of the polymorphic form of entacapone using an electrochemical tuneable surface template." CrystEngComm 16, no. 17 (2014): 3487–93. http://dx.doi.org/10.1039/c3ce42473a.

Full text

Abstract:

At open circuit potentials (OCP) entacapone crystallises onto the surface of a gold nucleation template in its stable polymorphic form A whilst at negative polarization (−150 mV) this behavior is suppressed and the polymorphic form is switched to the formation of the metastable α-form which nucleates at the template's edges.

APA, Harvard, Vancouver, ISO, and other styles

41

Facharztmagazine, Redaktion. "Dreifach-Wirkstoff-Kombination mit Entacapon." DNP - Der Neurologe & Psychiater 22, no. 3 (2021): 63–68. http://dx.doi.org/10.1007/s15202-021-4695-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Hwang, InKoo, DaeYoung Yoo, HyoYoung Jung, et al. "Entacapone promotes hippocampal neurogenesis in mice." Neural Regeneration Research 16, no. 6 (2021): 1005. http://dx.doi.org/10.4103/1673-5374.300447.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

&NA;. "Rasagiline, entacapone dominate levodopa in Finland." Inpharma Weekly &NA;, no. 1518 (2005): 6. http://dx.doi.org/10.2165/00128413-200515180-00010.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

LOWRY, FRAN. "Entacapone Blunts Cravings in Marijuana Users." Clinical Psychiatry News 37, no. 3 (2009): 30. http://dx.doi.org/10.1016/s0270-6644(09)70085-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Foti, Caterina, Nicoletta Cassano, Michele De Mari, Margherita Sorino, and Gino A. Vena. "Bullous skin eruption associated with entacapone." International Journal of Dermatology 43, no. 6 (2004): 471–72. http://dx.doi.org/10.1111/j.1365-4632.2004.02081.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Seeberger, Lauren C., and Robert A. Hauser. "Levodopa/carbidopa/entacapone in Parkinson’s disease." Expert Review of Neurotherapeutics 9, no. 7 (2009): 929–40. http://dx.doi.org/10.1586/ern.09.64.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Fisher, Alexander, James Croft-Baker, Michael Davis, Patrick Purcell, and Allan J. McLean. "Entacapone-Induced Hepatotoxicity and Hepatic Dysfunction." Movement Disorders 17, no. 6 (2002): 1362–65. http://dx.doi.org/10.1002/mds.10342.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Beck, Simon, Jean Hubble, and Kari Reinikainen. "Entacapone-induced hepatotoxicity and hepatic dysfunction." Movement Disorders 17, no. 6 (2002): 1397–99. http://dx.doi.org/10.1002/mds.10369.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Wollmer, Erik, and Sandra Klein. "Development and Validation of a Robust and Efficient HPLC Method for the Simultaneous Quantification of Levodopa, Carbidopa, Benserazide and Entacapone in Complex Matrices." Journal of Pharmacy & Pharmaceutical Sciences 20 (July 27, 2017): 258. http://dx.doi.org/10.18433/j3k923.

Full text

Abstract:

Purpose: A variety of fixed-dose combination products is used in the therapy of Parkinson Disease. However, to date a proper analytical method applicable for comparative screening of different antiparkinson products was not available. The objective of the present work was thus to develop and validate an analytical method for the simultaneous quantification of levodopa, carbidopa, benserazide and entacapone. The method should be applicable for quantifying samples from drug release experiments with marketed products and prototype formulations performed under compendial and biorelevant test condi

APA, Harvard, Vancouver, ISO, and other styles

50

Forsberg, Markus, Jouko Savolainen, Tomi Järvinen, Jukka Leppänen, Jukka Gynther, and Pekka T. Männistö. "Pharmacodynamic Response of Entacapone in Rats after Administration of Entacapone Formulations and Prodrugs with Varying Bioavailabilities." Pharmacology & Toxicology 90, no. 6 (2002): 327–32. http://dx.doi.org/10.1034/j.1600-0773.2002.900606.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!